GLP1R and metabolic dysfunction-associated steatohepatitis: Specifically, pioglitazone and GLP-1 receptor agonists (mostly subcutaneous liraglutide and semaglutide) improved individual histological features of NASH or achieved histological resolution of NASH without worsening of fibrosis.